DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

Today, Benzinga 's options scanner spotted 9 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 22% bullish and 66%, bearish. Out ...

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug ...

A large majority of RRMS patients experienced no evidence of disease activity for up to six years on Tysabri, a real-world ...

We recently published a list of 10 Cheap NASDAQ Stocks To Invest In Now. In this article, we are going to take a look at ...

combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis ...

and Biogen (Avonex, which treats multiple sclerosis, or MS). By adding the popular Spinraza for spinal muscular atrophy, or SMA, a rare neuromuscular condition, the company broadened its neurology ...

Multiple sclerosis (MS) is a chronic neurological disorder affecting ... Denali Therapeutics Inc., Sanofi, MediciNova, Biogen, Tiziana Life Sciences, Antisense Therapeutics, RemeGen, Atara ...

While multiple sclerosis products continued to be the top earners for Biogen with collective sales of roughly $1.1 billion, the business was down 9% from 2023’s third quarter, which Biogen’s ...

Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...